BACKGROUND: Approximately 20% of patients with idiopathic dilated cardiomyopathy (iDCM) have autoantibodies (AAbs) specific to cardiac troponin-I (cTnI). However, there has been no work evaluating active cellular autoimmunity. We aimed to identify a cTnI-stimulated cellular autoimmune response and to correlate our findings with cTnI AAb production. METHODS: Samples were obtained from stable ambulatory iDCM patients and healthy controls. Peripheral blood monocytes were incubated with cTnI, and cellular proliferation was measured using flow cytometry. AAbs against cTnI were detected by enzyme-linked immunosorbent assay. RESULTS: A positive cellular proliferative response to cTnI was identified in 20.5% (9/44) patients with iDCM and 5.7% (2/35) of healthy controls (p < 0.05). Positive cTnI AAbs were identified in 20% (7/35) of healthy controls and 13.6% (6/44) of patients with iDCM (p = NS). The presence of cTnI AAbs did not correlate with a positive cellular proliferative response. However, patients with iDCM who had an AAb response to cTnI were less likely to be taking a statin (p < 0.05). CONCLUSIONS: A cellular autoimmune response to cTnI is demonstrated in a subset of patients with iDCM. However, the presence of a cellular response did not correlate with the presence of AAbs to the same antigen.
BACKGROUND: Approximately 20% of patients with idiopathic dilated cardiomyopathy (iDCM) have autoantibodies (AAbs) specific to cardiac troponin-I (cTnI). However, there has been no work evaluating active cellular autoimmunity. We aimed to identify a cTnI-stimulated cellular autoimmune response and to correlate our findings with cTnIAAb production. METHODS: Samples were obtained from stable ambulatory iDCM patients and healthy controls. Peripheral blood monocytes were incubated with cTnI, and cellular proliferation was measured using flow cytometry. AAbs against cTnI were detected by enzyme-linked immunosorbent assay. RESULTS: A positive cellular proliferative response to cTnI was identified in 20.5% (9/44) patients with iDCM and 5.7% (2/35) of healthy controls (p < 0.05). Positive cTnIAAbs were identified in 20% (7/35) of healthy controls and 13.6% (6/44) of patients with iDCM (p = NS). The presence of cTnIAAbs did not correlate with a positive cellular proliferative response. However, patients with iDCM who had an AAb response to cTnI were less likely to be taking a statin (p < 0.05). CONCLUSIONS: A cellular autoimmune response to cTnI is demonstrated in a subset of patients with iDCM. However, the presence of a cellular response did not correlate with the presence of AAbs to the same antigen.
Authors: J E Parrillo; R E Cunnion; S E Epstein; M M Parker; A F Suffredini; M Brenner; G L Schaer; S T Palmeri; R O Cannon; D Alling Journal: N Engl J Med Date: 1989-10-19 Impact factor: 91.245
Authors: Ziya Kaya; Stefan Göser; Sebastian J Buss; Florian Leuschner; Renate Ottl; Jin Li; Mirko Völkers; Stefan Zittrich; Gabriele Pfitzer; Noel R Rose; Hugo A Katus Journal: Circulation Date: 2008-10-27 Impact factor: 29.690
Authors: Michael P Crawford; Shirley X Yan; Sterling B Ortega; Riyaz S Mehta; Rachel E Hewitt; David A Price; Peter Stastny; Daniel C Douek; Richard A Koup; Michael K Racke; Nitin J Karandikar Journal: Blood Date: 2004-02-19 Impact factor: 22.113
Authors: Eduardo M Vilela; Rita Bettencourt-Silva; J Torres da Costa; Ana Raquel Barbosa; Marisa P Silva; Madalena Teixeira; João Primo; Vasco Gama Ribeiro; José Pedro L Nunes Journal: Ann Transl Med Date: 2017-08